Table 1:
Characteristics of the patients at baseline*
| Characteristics | N | All (N=779) | Without Leukapheresis (N=666) | Leukapheresis (N=113) | P |
|---|---|---|---|---|---|
| Median Age in years (IQR) | 778 | 55(41–66) | 55(42–66) | 55(38–65) | 0.459 |
| Female Sex | 779 | 381 (48.9%) | 325 (48.8%) | 56 (49.6%) | 0.919 |
| ECOG performance status <2 | 640 | 421 (65.8%) | 388 (66.9%) | 33 (55%) | 0.085 |
| WHO Type (%) | 278 | <0.001 | |||
| AML with recurrent genetic abnormalities | 89 (32%) | 75 (38.3%) | 14 (17.1%) | ||
| AML with myelodysplasia-related features | 23 (8.3%) | 16 (8.2%) | 7 (8.5%) | ||
| AML, not otherwise specified | 148 (53.2%) | 89 (45.4%) | 59 (72%) | ||
| Therapy-related AML | 18 (6.5%) | 16 (8.2%) | 2 (2.4%) | ||
| Cytogenetic/ molecular characteristics | 674 | <0.001 | |||
| Favorable cytogenetic risk | 155(23.6%) | 153(27.6%) | 2(2.0%) | ||
| Intermediate cytogenetic risk | 392(59.8%) | 314(56.5%) | 78(77.2%) | ||
| Unfavorable cytogenetic risk | 109(16.6%) | 88(15.9%) | 21(20.8%) | ||
| Complex Cytogenetics | 453 | 55 (12.1%) | 43 (11.4%) | 12 (16%) | 0.251 |
| Monosomy Karyotype | 398 | 17 (4.3%) | 15 (4.3%) | 2 (4.2%) | >0.999 |
| NPM1 mutation | 444 | 208 (46.8%) | 170 (45.2%) | 38 (55.9%) | 0.114 |
| FLT3 mutation | 518 | 264 (51%) | 198 (45.9%) | 66 (75.9%) | <0.001 |
| Complete Blood Count | |||||
| Median WBC (IQR) | 779 | 110(77–170) | 103(73–152) | 175(127–246) | <0.001 |
| Median HB (IQR) | 772 | 9.2(7.8–10.9) | 9.2(7.7–11) | 9.3(7.8–10.6) | 0.852 |
| Median Platelets (IQR) | 775 | 31(11–72) | 25(10.4–67) | 46.5(21.5–90) | <0.001 |
| Blast % | |||||
| Median Peripheral Blood Blast (IQR) | 512 | 75(41–90) | 74(37.2–88) | 82.5(61–93.8) | 0.004 |
| Median Bone Marrow Blast (IQR) | 438 | 83(64–91) | 82(61.4–91) | 85(76–91.8) | 0.034 |
| Clinical Presentation | |||||
| Leukostasis | 740 | 201 (27.2%) | 139 (22.1%) | 62 (55.9%) | <0.001 |
| TLS | 742 | 209 (28.2%) | 189 (29.3%) | 20 (20.8%) | 0.09 |
| DIC | 581 | 106 (18.2%) | 86 (17.8%) | 20 (20.4%) | 0.566 |
| Hyperleukocytosis Management | 754 | <0.001 | |||
| Hydroxyurea followed by IC | 304 (40.3%) | 301 (47%) | 3 (2.7%) | ||
| Immediate initiation of IC | 341 (45.2%) | 340 (53%) | 1 (0.9%) | ||
| Leukapheresis followed by delayed (after 24h) IC | 41 (5.4%) | 0 (0%) | 41 (36.3%) | ||
| Leukapheresis followed by immediate (within 24h) IC | 68 (9%) | 0 (0%) | 68 (60.2%) | ||
| Organs affected by Leukostasis | 176 | 0.272 | |||
| Pulmonary leukostasis | 77 (43.8%) | 34 (42.5%) | 43 (44.8%) | ||
| CNS Leukostasis | 63 (35.8%) | 28 (35%) | 35 (36.5%) | ||
| Retinal Leukostasis | 11 (6.3%) | 3 (3.75%) | 8 (8.3%) | ||
| Renal Failure | 9 (5.1%) | 4 (5%) | 5 (5.2%) | ||
| Chest Pain/MI | 10 (5.7%) | 8 (10%) | 2 (2.1%) | ||
| GI Leukostasis | 6 (3.4%) | 3 (3.75%) | 3 (3.1%) | ||
*
For continuous variables, t-test or Wilcoxon rank sum test was used to compare the difference between treatment groups, depending on the distribution of data. For categorical variables, Fisher’s exact test was used to examine the association with treatment groups. IQR denotes interquartile range.